Myostatin and Sarcopenia: Opportunities and Challenges - A Mini-Review
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
The progressive loss of skeletal muscle mass, strength and/or function with advancing age, termed sarcopenia, poses a major threat to independence and quality of life. Therefore, there is significant merit in better understanding the biology of sarcopenia and developing therapeutic interventions to prevent, slow or reverse its progression. Since the discovery of myostatin, a potent negative regulator of growth that is highly enriched in skeletal muscle, there has been great interest in it as a potential mediator of sarcopenia as well as a therapeutic target. The complex biology of myostatin, the promise of myostatin inhibition as an effective means to counter sarcopenia, and the challenges facing its clinical translation are reviewed herein.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Myostatin is also expressed in adipose tissue and is inversely related to insulin resistance445.”
From Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies (2018) · cites this paper as [445]
In the citing paper
“Myostatin expression increases in skeletal muscle due to obesity and IR. Thus, it could favor the loss of skeletal muscle in SO [14, 61, 62].”
From The critical role of oxidative stress in sarcopenic obesity (2021) · cites this paper as [62]
In the citing paper
“Production of myostatin, a growth-inhibiting myokine, is upregulated in sarcopenia64, whereas that of muscle-mass-stimulating irisin seems to be downregulated65.”
From Sarcopenic obesity in older adults: a clinical overview (2024) · cites this paper as [64]
Citations
Cites
Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member
McPherron, A. C., Lawler, A. M., & Lee, S.-J. (1997) · Nature · doi:10.1038/387083a0 · Cited by 4,013
Regulation of myostatin activity and muscle growth
Lee, S.-J., & McPherron, A. C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151270098 · Cited by 1,616
Myostatin Mutation Associated with Gross Muscle Hypertrophy in a Child
Schuelke, M., Wagner, K. R., Stolz, L. E., Hübner, C., Riebel, T., Kömen, W., Braun, T., Tobin, J. F., & Lee, S.-J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040933 · Cited by 1,399
Myostatin Inhibits Myoblast Differentiation by Down-regulating MyoD Expression
Langley, B., Thomas, M., Bishop, A., Sharma, M., Gilmour, S., & Kambadur, R. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204291200 · Cited by 908
Mosher, D. S., Quignon, P., Bustamante, C. D., Sutter, N. B., Mellersh, C. S., Parker, H. G., & Ostrander, E. A. (2007) · PLoS Genetics · doi:10.1371/journal.pgen.0030079 · Cited by 826
REGULATION OF MUSCLE MASS BY MYOSTATIN
Lee, S.-J. (2004) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.20.012103.135836 · Cited by 819
Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size
Trendelenburg, A. U., Meyer, A., Rohner, D., Boyle, J., Hatakeyama, S., & Glass, D. J. (2009) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00105.2009 · Cited by 792
Smad2 and 3 transcription factors control muscle mass in adulthood
Sartori, R., Milan, G., Patron, M., Mammucari, C., Blaauw, B., Abraham, R., & Sandri, M. (2009) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00104.2009 · Cited by 517
Suppression of body fat accumulation in myostatin-deficient mice
McPherron, A. C., & Lee, S.-J. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0213562 · Cited by 505
Inhibition of myostatin in adult mice increases skeletal muscle mass and strength
Whittemore, L.-A., Song, K., Li, X., Aghajanian, J., Davies, M., Girgenrath, S., Hill, J. J., Jalenak, M., Kelley, P., Knight, A., et al. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02953-4 · Cited by 503
Research works printed but not linked: 1
- 10.1172/JCI13562 · doi:10.1172/jci13562 · Paper page
Cited by
Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies
Batsis, J. A., & Villareal, D. T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0062-9 · Cited by 1,382
Skeletal muscle performance and ageing
Tieland, M., Trouwborst, I., & Clark, B. C. (2018) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12238 · Cited by 904
“therapy for sarcopenia, which could affect skeletal muscle performance.(208)”
Sarcopenia: A Contemporary Health Problem among Older Adult Populations
Papadopoulou, S. (2020) · Nutrients · doi:10.3390/nu12051293 · Cited by 588
Sarcopenia: burden and challenges for public health
Beaudart, C., Rizzoli, R., Bruyère, O., Reginster, J.-Y., & Biver, E. (2014) · Archives of Public Health · doi:10.1186/2049-3258-72-45 · Cited by 495
“be the inhibition of myostatin, a regulator of muscle development and growth [59,60].”
BackgroundCai, Y., Song, W., Li, J., Jing, Y., Liang, C., Zhang, L., Zhang, X., Zhang, W., Liu, B., An, Y., et al. (2022) · Science China Life Sciences · doi:10.1007/s11427-022-2161-3 · Cited by 408
Yoshimura, Y., Wakabayashi, H., Yamada, M., Kim, H., Harada, A., & Arai, H. (2017) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2017.03.019 · Cited by 365
Sarcopenic obesity in older adults: a clinical overview
Prado, C. M., Batsis, J. A., Donini, L. M., Gonzalez, M. C., & Siervo, M. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00943-z · Cited by 355
“Production of myostatin, a growth-inhibiting myokine, is upregulated in sarcopenia 64 , whereas that of muscle-mass-stimulating irisin seems to be downregulated 65 .”
The integration of inflammaging in age-related diseases
Fulop, T., Witkowski, J. M., Olivieri, F., & Larbi, A. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.09.003 · Cited by 348
Sarcopenia and sarcopenic obesity
Choi, K. M. (2016) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2016.193 · Cited by 344
“Myostatin has emerged as a potential mediator of sarcopenia and a promising therapeutic target [31].”
BackgroundOsteoporosis and Sarcopenia Increase Frailty Syndrome in the Elderly
Greco, E. A., Pietschmann, P., & Migliaccio, S. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00255 · Cited by 335
Sinclair, M., Gow, P. J., Grossmann, M., & Angus, P. W. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13549 · Cited by 316
“Elevated myostatin levels are thought to be one of the major driving forces underlying the sarcopenia of ageing, however, the reasons for this elevation are not fully understood.(19)”
BackgroundMyokines: The endocrine coupling of skeletal muscle and bone
(2020) · Advances in Clinical Chemistry · doi:10.1016/bs.acc.2019.07.010 · Cited by 272
Role of exercise in age-related sarcopenia
Yoo, S.-Z., No, M.-H., Heo, J.-W., Park, D.-H., Kang, J.-H., Kim, S. H., & Kwak, H.-B. (2018) · Journal of Exercise Rehabilitation · doi:10.12965/jer.1836268.134 · Cited by 245
“Indeed, Yarasheski et al. (2002) reported that increases in serum myostatin levels were highest in physically frail older women and that they were inversely associated with skeletal muscle mass (White and LeBrasseur, 2014).”
BackgroundWalker, R. G., Poggioli, T., Katsimpardi, L., Buchanan, S. M., Oh, J., Wattrus, S., Heidecker, B., Fong, Y. W., Rubin, L. L., Ganz, P., et al. (2016) · Circulation Research · doi:10.1161/circresaha.116.308391 · Cited by 209
Quantification of GDF11 and Myostatin in Human Aging and Cardiovascular Disease
Schafer, M. J., Atkinson, E. J., Vanderboom, P. M., Kotajarvi, B., White, T. A., Moore, M. M., Bruce, C. J., Greason, K. L., Suri, R. M., Khosla, S., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.05.023 · Cited by 206
“Accordingly, therapeutic strategies to block MSTN signaling are aggressively being pursued as a means to improve muscle mass and function in the context of aging and disease (White and LeBrasseur, 2014).”
BackgroundSelf-citationSarcopenia – The search for emerging biomarkers
Kalinkovich, A., & Livshits, G. (2015) · Ageing Research Reviews · doi:10.1016/j.arr.2015.05.001 · Cited by 187
“, by FST, see below), and lack of reliable myostatin detection methods (Breitbart et al., 2013; Sakuma et al., 2015; White and LeBrasseur, 2014).”
Sex-specific differences in risk factors for sarcopenia amongst community-dwelling older adults
Tay, L., Ding, Y. Y., Leung, B. P., Ismail, N. H., Yeo, A., Yew, S., Tay, K. S., Tan, C. H., & Chong, M. S. (2015) · AGE · doi:10.1007/s11357-015-9860-3 · Cited by 174
“Further, it has been suggested that measured serum myostatin levels may not reflect myostatin activity, owing to its secretion as a precursor protein and regulation by its antagonist follistatin (White and LeBrasseur 2014).”
BackgroundMolecular mechanism of sarcopenia and cachexia: recent research advances
Sakuma, K., Aoi, W., & Yamaguchi, A. (2017) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-016-1933-3 · Cited by 169
Sarcopenic obesity: molecular clues to a better understanding of its pathogenesis?
Kob, R., Bollheimer, L. C., Bertsch, T., Fellner, C., Djukic, M., Sieber, C. C., & Fischer, B. E. (2015) · Biogerontology · doi:10.1007/s10522-014-9539-7 · Cited by 151
“Therefore, the possibility of using myostatin as a potential target for the therapy of sarcopenia deserves further investigation (White and LeBrasseur 2014).”
BackgroundExercise therapy for people with sarcopenic obesity: myokines and adipokines as effective actors
Alizadeh Pahlavani, H. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.811751 · Cited by 145
Bergen, H. R., Farr, J. N., Vanderboom, P. M., Atkinson, E. J., White, T. A., Singh, R. J., Khosla, S., & LeBrasseur, N. K. (2015) · Skeletal Muscle · doi:10.1186/s13395-015-0047-5 · Cited by 137
“As highlighted here and previously [31, 32], there are several challenges to the specific and accurate measurement of circulating myostatin concentrations using traditional antibody-based approaches, such as RIA, ELISA, and Western blotting.”
Self-citationMyostatin and its Regulation: A Comprehensive Review of Myostatin Inhibiting Strategies
Baig, M. H., Ahmad, K., Moon, J. S., Park, S.-Y., Ho Lim, J., Chun, H. J., Qadri, A. F., Hwang, Y. C., Jan, A. T., Ahmad, S. S., et al. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.876078 · Cited by 135
Liu, D., Wang, S., Liu, S., Wang, Q., Che, X., & Wu, G. (2024) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2024.101270 · Cited by 168
Hodes, R. J., Sierra, F., Austad, S. N., Epel, E., Neigh, G. N., Erlandson, K. M., Schafer, M. J., LeBrasseur, N. K., Wiley, C., Campisi, J., et al. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13299 · Cited by 132
Self-citationCurrent understanding of sarcopenia: possible candidates modulating muscle mass
Sakuma, K., Aoi, W., & Yamaguchi, A. (2014) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-014-1527-x · Cited by 148
Vitamin D, a modulator of musculoskeletal health in chronic kidney disease
Molina, P., Carrero, J. J., Bover, J., Chauveau, P., Mazzaferro, S., & Ureña, P. (2017) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12218 · Cited by 149
“reduces myostatin in cultured muscle cells, a hormone released from the muscle that inhibits muscle growth.(58,59) A”
BackgroundExercise-induced myokines and their effect on prostate cancer
Kim, J., Galvao, D. A., Newton, R. U., Gray, E. S., & Taaffe, D. R. (2021) · Nature Reviews Urology · doi:10.1038/s41585-021-00476-y · Cited by 144
Bone and Muscle Crosstalk in Aging
He, C., He, W., Hou, J., Chen, K., Huang, M., Yang, M., Luo, X., & Li, C. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.585644 · Cited by 149
The clinical impact and biological mechanisms of skeletal muscle aging
Aversa, Z., Zhang, X., Fielding, R. A., Lanza, I., & LeBrasseur, N. K. (2019) · Bone · doi:10.1016/j.bone.2019.05.021 · Cited by 101
Self-citationDowling, P., Gargan, S., Swandulla, D., & Ohlendieck, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032415 · Cited by 109
Osteosarcopenic obesity and fall prevention strategies
Hita‐Contreras, F., Martínez‐Amat, A., Cruz‐Díaz, D., & Pérez-López, F. R. (2014) · Maturitas · doi:10.1016/j.maturitas.2014.11.009 · Cited by 101
Chew, J., Tay, L., Lim, J. P., Leung, B. P., Yeo, A., Yew, S., Ding, Y. Y., & Lim, W. S. (2019) · The Journal of nutrition, health and aging · doi:10.1007/s12603-019-1255-1 · Cited by 88
Sarcopenic obesity: Myokines as potential diagnostic biomarkers and therapeutic targets?
Guo, A., Li, K., & Xiao, Q. (2020) · Experimental Gerontology · doi:10.1016/j.exger.2020.111022 · Cited by 83
Cellular senescence: Implications for metabolic disease
Schafer, M. J., Miller, J. D., & LeBrasseur, N. K. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2016.08.047 · Cited by 83
“associated changes in skeletal muscle mass and composition contribute to systemic metabolic decline [78-80].”
BackgroundSelf-citationMuscle-Bone Crosstalk in the Masticatory System: From Biomechanical to Molecular Interactions
Buvinic, S., Balanta‐Melo, J., Kupczik, K., Vásquez, W., Beato, C., & Toro‐Ibacache, V. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.606947 · Cited by 93
The critical role of oxidative stress in sarcopenic obesity
Gonzalez, A., Simon, F., Achiardi, O., Vilos, C., Cabrera, D., & Cabello-Verrugio, C. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/4493817 · Cited by 79
“Thus, it could favor the loss of skeletal muscle in SO [14, 61, 62].”
BackgroundLadang, A., Beaudart, C., Reginster, J., Al‐Daghri, N. M., Bruyère, O., Burlet, N., Cesari, M., Cherubini, A., da Silva, M. C., Cooper, C. C., et al. (2023) · Calcified Tissue International · doi:10.1007/s00223-022-01054-z · Cited by 98
Bone muscle interactions and vitamin D
Gunton, J. E., Girgis, C. M., Baldock, P. A. J., & Lips, P. T. A. M. (2015) · Bone · doi:10.1016/j.bone.2015.02.029 · Cited by 85
“Interestingly, the notion of direct humoral interactions between bone and muscle has also been supported by studies such as those of myostatin, a powerful inhibitor of muscle growth (reviewed in [50]), which also has powerful effects upon bone mass and fracture healing, independent of the changes inmuscle strength [51…”
ResultGeriatric syndromes: new frontiers in HIV and sarcopenia
Hawkins, K. L., Brown, T. T., Margolick, J. B., & Erlandson, K. M. (2017) · AIDS · doi:10.1097/qad.0000000000001444 · Cited by 94
“– a potent negative regulator of muscle growth – has increased muscle mass and strength in both young and old mice after 4 weeks of therapy, and holds promise as an agent to further investigate as a therapeutic option for sarcopenia [126,127].”
BackgroundFife, E., Kostka, J., Kroc, Ł., Guligowska, A., Pigłowska, M., Sołtysik, B., Kaufman-Szymczyk, A., Fabianowska-Majewska, K., & Kostka, T. (2018) · BMC Geriatrics · doi:10.1186/s12877-018-0888-y · Cited by 77
Planella-Farrugia, C., Comas, F., Sabater-Masdeu, M., Moreno, M., Moreno-Navarrete, J. M., Rovira, O., Ricart, W., & Fernández-Real, J. M. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00871 · Cited by 73
Sheng, R., Cao, M., Song, M., Wang, M., Zhang, Y., Shi, L., Xie, T., Li, Y., Wang, J., & Rui, Y. (2023) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2023.09.007 · Cited by 91
“These disparate results highly suggested that increased myostatin could be not a primary cause of sarcopenia or osteosarcopenia [40] and could be caused by different features of study cohorts (e.g., age, sex, basic diseases) and various measurements for myostatin and skeletal muscle mass.…”
BackgroundVascular Impairment, Muscle Atrophy, and Cognitive Decline: Critical Age-Related Conditions
de Lima, E. P., Tanaka, M., Lamas, C. B., Quesada, K., Detregiachi, C. R. P., Araújo, A. C., Guiguer, E. L., Catharin, V. M. C. S., de Castro, M. V. M., Junior, E. B., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12092096 · Cited by 73
Hofmann, M., Halper, B., Oesen, S., Franzke, B., Stuparits, P., Tschan, H., Bachl, N., Strasser, E.-M., Quittan, M., Ploder, M., et al. (2015) · Experimental Gerontology · doi:10.1016/j.exger.2015.02.008 · Cited by 85
Pathophysiology of sarcopenia: Genetic factors and their interplay with environmental factors
Aslam, M. A., Ma, E. B., & Huh, J. Y. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155711 · Cited by 84
The Intriguing Regulators of Muscle Mass in Sarcopenia and Muscular Dystrophy
Sakuma, K., Aoi, W., & Yamaguchi, A. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00230 · Cited by 69
Myostatin: Basic biology to clinical application
Esposito, P. B., Picciotto, D., Battaglia, Y., Costigliolo, F., Viazzi, F. C., & Verzola, D. (2022) · Advances in clinical chemistry · doi:10.1016/bs.acc.2021.09.006 · Cited by 83
Arrieta, H., Hervás, G., Rezola-Pardo, C., Ruiz-Litago, F., Iturburu, M., Yanguas, J. J., Gil, S. M., Rodriguez-Larrad, A., & Irazusta, J. (2019) · Gerontology · doi:10.1159/000494137 · Cited by 66
Wetzlich, B., Nyakundi, B. B., & Yang, J. (2024) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-024-05120-y · Cited by 78
Reduced serum myostatin concentrations associated with genetic muscle disease progression
Burch, P. M., Pogoryelova, O., Palandra, J., Goldstein, R., Bennett, D., Fitz, L. J., Guglieri, M., Marini‐Bettolo, C., Straub, V. W., Evangelista, T., et al. (2017) · Journal of Neurology · doi:10.1007/s00415-016-8379-6 · Cited by 71
Alessandro de, S. I. R. E., Invernizzi, M., Baricich, A., Lippi, L., Ammendolia, A., Grassi, F. A., & Leigheb, M. (2021) · World Journal of Orthopedics · doi:10.5312/wjo.v12.i7.456 · Cited by 65
Sex Differences Research, Precision Medicine, and the Future of Women's Health
Miller, V. M., Rocca, W. A., & Faubion, S. S. (2015) · Journal of Women's Health · doi:10.1089/jwh.2015.5498 · Cited by 58
“With the aging of the population, investigation of sexspecific molecular pathways associated with age-related diseases such as sarcopenia are being pursued to understand how interventions may slow these processes.(17) Radiologists are working with neurologists to develop improved methods to detect sex-specific alterat…”
BackgroundThe role of TGF-β signaling in muscle atrophy, sarcopenia and cancer cachexia
Lan, X., Deng, C., Wang, Q., Zhao, L., Jiao, B., & Xiang, Y. (2024) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2024.114513 · Cited by 66
Griffen, C., Duncan, M., Hattersley, J., Weickert, M. O., Dallaway, A., & Renshaw, D. (2022) · Experimental Gerontology · doi:10.1016/j.exger.2021.111651 · Cited by 54
Quercetin glycosides prevent dexamethasone-induced muscle atrophy in mice
Otsuka, Y., Egawa, K., Kanzaki, N., Izumo, T., Rogi, T., & Shibata, H. (2019) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2019.100618 · Cited by 69
Delanaye, P., Bataille, S., Quinonez, K., Buckinx, F., Warling, X., Krzesinski, J.-M., Pottel, H., Burtey, S., Bruyère, O., & Cavalier, E. (2019) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2018.11.010 · Cited by 56
Alessandro de, S. I. R. E., Baricich, A., Renò, F., Cisari, C., Fusco, N., & Invernizzi, M. (2019) · Aging Clinical and Experimental Research · doi:10.1007/s40520-019-01436-8 · Cited by 53
Ryan, A. S., & Li, G. (2021) · JCSM Clinical Reports · doi:10.1002/crt2.43 · Cited by 51
“When applied to myoblasts, myostatin inhibits their differentiation into mature muscle fibres.(9)”
BackgroundMethodProteomic serum biomarkers for neuromuscular diseases
Murphy, S., Zweyer, M., Mundegar, R. R., Swandulla, D., & Ohlendieck, K. (2018) · Expert Review of Proteomics · doi:10.1080/14789450.2018.1429923 · Cited by 52
“tive regulator of skeletal muscle mass and growth, suggesting that the pharmacological inhibition of myostatin action may be an effective countermeasure to treat sarcopenia [89] and”
BackgroundPhysical exercise in kidney disease: A commonly undervalued treatment modality
Kanbay, M., Çöpür, S., Yıldız, A. B., Tanrıöver, C., Mallamaci, F., & Zoccali, C. (2023) · European Journal of Clinical Investigation · doi:10.1111/eci.14105 · Cited by 54
“72,73 73– 75 Further studies are needed to understand this association.”
BackgroundMoriwaki, K., Matsumoto, H., Tanishima, S., Tanimura, C., Osaki, M., Nagashima, H., & Hagino, H. (2019) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-019-2650-9 · Cited by 51
Conforto, R., Rizzo, V., Russo, R., Mazza, E., Maurotti, S., Pujia, C., Succurro, E., Arturi, F., Ferro, Y., Sciacqua, A., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156052 · Cited by 48
Association between Thigh Muscle Volume and Leg Muscle Power in Older Women
Lindemann, U., Mohr, C. H., Machann, J., Blatzonis, K., Rapp, K., & Becker, C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0157885 · Cited by 50
“The pharmaceutical industry has started trials for the development and evaluation of new medications [7] and non-pharmaceutical interventions [8,9].”
BackgroundKim, J., Lee, J.-Y., & Kim, C. Y. (2023) · Nutrients · doi:10.3390/nu15112625 · Cited by 48
“In contrast, the inhibited Akt/mTOR pathway in response to myostatin also suppresses protein synthesis [38].”
BackgroundSarcopenic Obesity: Involvement of Oxidative Stress and Beneficial Role of Antioxidant Flavonoids
Jung, U. J. (2023) · Antioxidants · doi:10.3390/antiox12051063 · Cited by 45
Emerging roles for histone deacetylases in age-related muscle atrophy
Walsh, M. E., & Remmen, H. V. (2016) · Nutrition and Healthy Aging · doi:10.3233/nha-160005 · Cited by 39
“Similarly, while HDAC inhibitors inhibit myostatin by increasing follistatin, there is not a clear role for myostatin in the development of sarcopenia [165].”
BackgroundLee, J., Kang, M., Yoo, J., Lee, S., Kang, M., Yun, B., Kim, J. N., Moon, H., Chung, Y., & Oh, S. (2023) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.2303.03001 · Cited by 45
“Myostatin affects skeletal muscle generation and growth by inhibiting Akt/mammalian target of rapamycin (mTOR) signaling and protein synthesis [66].”
Mechanisms of myostatin and activin A accumulation in chronic kidney disease
Bataille, S., Dou, L., Bartoli, M., Sallée, M., Aniort, J., Ferkak, B., Chermiti, R., McKay, N., Silva, N. D., Burtey, S., et al. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac136 · Cited by 40
Goljanek‐Whysall, K., Iwanejko, L., Vasilaki, A., Pekovic‐Vaughan, V., & McDonagh, B. (2016) · Mammalian Genome · doi:10.1007/s00335-016-9643-x · Cited by 40
Exploring exercise-driven exerkines: unraveling the regulation of metabolism and inflammation
Zhou, N., Gong, L., Zhang, E., & Wang, X. (2024) · PeerJ · doi:10.7717/peerj.17267 · Cited by 38
“MSTN plays a crucial role in muscle homeostasis, and its dysregulation has been associated with various muscle-related disorders, including sarcopenia and muscle-wasting diseases ( White & LeBrasseur, 2014 ).”
BackgroundMuraca, M., & Cappariello, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228682 · Cited by 38
“Serum levels of muscle-derived cytokine myostatin increase with progressing age both in men and in women and are inversely associated with skeletal muscle mass [145,146].”
BackgroundPreclinical insights into the gut‐skeletal muscle axis in chronic gastrointestinal diseases
Ehlers, L., Bannert, K., Rohde, S., Berlin, P., Reiner, J., Wiese, M. L., Doller, J., Lerch, M. M., Aghdassi, A. A., Meyer, F., et al. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15554 · Cited by 37
Ahmad, S. S., Ahmad, K., Lee, E. J., Shaikh, S., & Choi, I. (2021) · Molecules · doi:10.3390/molecules26175407 · Cited by 32
Yamada, S., Tsuruya, K., Yoshida, H., Tokumoto, M., Ueki, K., Ooboshi, H., & Kitazono, T. (2016) · Calcified Tissue International · doi:10.1007/s00223-016-0118-6 · Cited by 31
Muscle endocrinology and its relation with nutrition
Romagnoli, C., Pampaloni, B., & Brandi, M. L. (2019) · Aging Clinical and Experimental Research · doi:10.1007/s40520-019-01188-5 · Cited by 34
Park, J., Bae, J.-J., & Lee, J. (2021) · Healthcare · doi:10.3390/healthcare9060711 · Cited by 34
“[5] reported that physically frail elderly women showed the highest elevation of serum Mstn levels and that elevation of Mstn levels is negatively correlated with skeletal muscle mass; however, aging-related changes in circulating or muscle Mstn-immunoreactive protein levels or Mstn mRNA have not been proven [6].”
BackgroundGinseng and ginsenosides: Therapeutic potential for sarcopenia
Zha, W., Sun, Y., Gong, W., Li, L., Kim, W., & Li, H. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113876 · Cited by 33
Cannavò, A., Carandina, A., Corbi, G., Tobaldini, E., Montano, N., & Arosio, B. (2022) · Life · doi:10.3390/life12122139 · Cited by 34
Yoshimoto, Y., & Oishi, Y. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108357 · Cited by 30
Kuo, Y.-K., Lin, Y., Lee, C., Chen, C., Tani, J., Huang, T., Chang, H. C., & Wu, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21083010 · Cited by 32
Yang, C., Li, X., & Rong, J. (2014) · Chinese Medicine · doi:10.1186/1749-8546-9-23 · Cited by 29
“Myostatin has emerged as a molecular target for therapeutic intervention [5].”
BackgroundMitra, A., Qaisar, R., Bose, B., & Sudheer Shenoy, P. (2023) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2023.03.008 · Cited by 30
Vellas, B. J. (2015) · The journal of nutrition health & aging · doi:10.1007/s12603-015-0505-0 · Cited by 28
“This may lead to the identification of an objective and clinical target for non-pharmacological and pharmacological interventions (e.g., myostatin inhibitors currently under development) (44).”
Ito, T., Nakanishi, Y., Yamaji, N., Murakami, S., & Schaffer, S. W. (2018) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b17-00969 · Cited by 28
Crucial Regulatory Role of Organokines in Relation to Metabolic Changes in Non-Diabetic Obesity
Lőrincz, H., Somodi, S., Ratku, B., Harangi, M., & Paragh, G. (2023) · Metabolites · doi:10.3390/metabo13020270 · Cited by 27
Ge, L., Dong, X., Gong, X., Kang, J., Zhang, Y., & Quan, F. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.03.043 · Cited by 30
Identification of frailty and sarcopenia in hospitalised older people
Echeverria, I., Besga, A., Sanz, B., Amasene, M., Hervás, G., Barroso, J., Rodriguez‐Larrad, A., & Irazusta, J. (2020) · European Journal of Clinical Investigation · doi:10.1111/eci.13420 · Cited by 30
Seo, H., Lee, S.-H., Park, Y., Lee, H., Hong, J. S., Lim, C. Y., Kim, D. H., Park, S., Suh, H. J., & Hong, K. (2021) · Antioxidants · doi:10.3390/antiox10071026 · Cited by 29
Definition and diagnosis of sarcopenia: Asia-Pacific perspectives
Huang, W.-F., Chen, Y., Chang, C., & Wu, C. (2025) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2025.05.004 · Cited by 26
“While the role of myostatin in aging is not yet fully understood, its unique properties make it an attractive target for treating sarcopenia [87].”
Kim, M.-J., & O’Connor, M. B. (2020) · Development · doi:10.1242/dev.190868 · Cited by 30
Iyer, C. C., Chugh, D., Bobbili, P. J., Blatnik, A. J., Crum, A. E., Yi, A. F., Kaspar, B. K., Meyer, K., Burghes, A. H. M., & Arnold, W. D. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.03.005 · Cited by 26
Advance in Drug Delivery for Ageing Skeletal Muscle
Li, Y., Chen, M., Zhao, Y.-P., Li, M., Qin, Y., Cheng, S.-H., Yang, Y.-Y., Yin, P., Zhang, L.-C., & Tang, P. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01016 · Cited by 21
“Myostatin can combine with activin receptors type IIB (ActRIIB) on the myofibers membrane which regulate skeletal muscle mass and function (White and LeBrasseur, 2014).”
BackgroundAcute Sarcopenia after Elective and Emergency Surgery
Shrestha, A., Dani, M., Kemp, P. R., & Fertleman, M. B. (2022) · Aging and Disease · doi:10.14336/ad.2022.0404 · Cited by 26
O’Hara, V., Cowan, A., Riddell, D. O., Massey, C., Martin, J., & Piercy, R. J. (2021) · Scientific Reports · doi:10.1038/s41598-021-86783-1 · Cited by 22
González-Luis, A., Llinares-Arvelo, V., Martínez‐Alberto, C. E., Hernández-Carballo, C., Fernández, C. M., Navarro‐González, J. F., & Donate‐Correa, J. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf223 · Cited by 23
Sarcopenia in Liver Transplantation: an Update
Dhaliwal, A., Williams, F. R., El‐Sherif, O., & Armstrong, M. J. (2020) · Current Hepatology Reports · doi:10.1007/s11901-020-00515-z · Cited by 21
Variants in the Myostatin Gene and Physical Performance Phenotype of Elite Athletes
Ginevičienė, V., Jakaitienė, A., Pranckevičienė, E., Milašius, K., & Utkus, A. (2021) · Genes · doi:10.3390/genes12050757 · Cited by 19
“These phenotypic consequences include muscle strength [1,13,16], endurance performance [17], left ventricular mass [18], peak bone mineral density [19], sarcopenia [15,20,21], Duchenne muscular dystrophy [22], and obesity [11,23], among others [7,8,14].”
BackgroundAssociation between Serum GDF-15, Myostatin, and Sarcopenia in Cardiovascular Surgery Patients
Nishikawa, R., Fukuda, T., Haruyama, A., Shibasaki, I., Yamaguchi, S., Arikawa, T., Obi, S., Amano, H., Yagi, H., Sakuma, M., et al. (2022) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2022.101114 · Cited by 23
“The progressive age-related loss of skeletal muscle mass, strength, and muscle function, termed sarcopenia, is a major threat to selfsufficiency and quality of life [1].”
BackgroundSkrzypczak, D., Skrzypczak-Zielińska, M., Ratajczak, A. E., Szymczak‐Tomczak, A., Eder, P., Słomski, R., Dobrowolska, A., & Krela‐Kaźmierczak, I. (2021) · Biomedicines · doi:10.3390/biomedicines9101301 · Cited by 21
“Moreover, it may also protect against cachexia, and support the regeneration of the muscle tissue following trauma or neurodegenerative diseases [22].”
BackgroundInfluentialPerry, C. A., Van Guilder, G. P., & Butterick, T. A. (2022) · BMC Nutrition · doi:10.1186/s40795-022-00516-9 · Cited by 16
Metadata
- Authors
- White, T. A., & LeBrasseur, N. K.
- Affiliations
- Mayo Clinic (US)
- Venue
- Gerontology
- Publisher
- S. Karger AG
- Published
- 2014
- Volume
- 60
- Issue
- 4
- Pages
- 289-293
- ISSN
- 0304-324X (ISSN-L)
- 1423-0003
- OpenAlex
- W2006774297
- Cited by
- 191
- References
- 32
- Citations by year
- 2026: 11 · 2025: 12 · 2024: 14 · 2023: 23 · 2022: 17 · 2021: 25 · 2020: 17 · 2019: 16 · 2018: 12 · 2017: 13 · 2016: 14 · 2015: 7 · 2014: 10
- FWCI
- 1.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Gerontology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Mayo Clinic
- Center for Cell Signaling in Gastroenterology, Mayo Clinic
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK084567)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Keywords
- myostatin, sarcopenia, skeletal muscle atrophy, muscle strength, aging, myostatin inhibition, therapeutic target, clinical translation, muscle growth regulation
- MeSH terms
- Aged, Aging, Animals, Humans, Signal Transduction, Muscle, Skeletal, Mice, Myostatin, Sarcopenia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.